Phase I-B results for nintedanib DPI in IPF patients showed a clean safety profile, with no serious adverse events, no GI issues, and transient mild-to-moderate cough in a minority of patients. The drug achieved efficient lung delivery and is advancing to a global phase II trial with broad patient inclusion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.